OS (p) | LRC (p) | DFS (p) | |
---|---|---|---|
Gender: | |||
male (N = 45) | 0.16 | 0.46 | 0.63 |
female (N = 10) | |||
Age: | |||
≤ 62 years (N = 29) | 0.16 | 0.6 | 0.85 |
> 62 years (N = 26) | |||
WHO performance stage: | |||
0–1 (N = 50) | 0.99 | 0.78 | 0.95 |
2 (N = 5) | |||
Risk factors: | |||
none present (N = 19) | 0.67 | 0.24 | 0.23 |
at least one present (N = 36) | |||
Tumor localization: | |||
upper third - cervical (N = 32) | 0.18 | 0.56 | 0.57 |
middle third - intrathoracic (N = 23) | |||
T stage: | |||
T 1+2 (N = 8) | 0.38 | 0.76 | 0.37 |
T 3+4 (N = 47) | |||
N stage: | |||
N0 (N = 20) | 0.79 | 0.22 | 0.42 |
N+ (N = 35) | |||
Treatment schedule: | |||
definitive radiochemotherapy (N = 49) | 0.66 | 0.55 | 0.46 |
TD on tumor: | |||
≤ 57.6 Gy (N = 35) | 0.61 | 0.52 | 0.79 |
> 57.6 Gy (N = 20) |
Chemotherapy regimen used | N (%) |
---|---|
5-FU in continuous 96 hours infusion + cisplatin | 41 (74.5) |
Weekly cisplatin only during RT | 3 (5.5) |
Paclitaxel + carboplatin | 2 (3.6) |
5-FU + carboplatin | 2 (3.6) |
Induction TCF followed by weekly cisplatin during RT | 1 (1.8) |
Induction 5-FU + cisplatin followed by weekly carboplatin during RT | 1 (1.8) |
Induction paclitaxel + carboplatin followed by weekly carboplatin during RT | 1 (1.8) |
Induction weekly cisplatin followed by weekly carboplatin during RT | 1 (1.8) |
Induction paclitaxel + carboplatin followed by 5-FU + cisplatin during RT | 1 (1.8) |
Induction capecitabine + cisplatin followed by weekly cisplatin during RT | 1 (1.8) |
No chemotherapy given | 1 (1.8) |
Side effect | Grade | |||
---|---|---|---|---|
0 | 1 | 2 | 3 | |
Esophagitis | 6 (10.9) | 21 (38.2) | 17 (30.9) | 10 (18.2) |
Radiodermatitis | 35 (63.3) | 8 (14.5) | 7 (12.7) | 4 (7.3) |
Nausea | 40 (72.7) | 9 (16.4) | 4 (7.3) | 1 (1.8) |
Vomiting | 50 (90.9) | 1 (1.8) | 3 (5.5) | 0 |
Neutropenia | 25 (45.5) | 8 (14.5) | 10 (18.2) | 12 (21.8) |
Thrombocytopenia | 20 (36.4) | 21 (38.2) | 8 (14.5) | 6 (10.9) |
Anemia | 6 (10.9) | 27 (49.1) | 21 (38.2) | 1 (1.8) |
N (%) | |
---|---|
Gender | |
male | 45 (81.8) |
female | 10 (18.2) |
Age at diagnosis (years) | mean: 62 (SD |
WHO performance stage | |
0 | 24 (43.6) |
1 | 26 (47.3) |
2 | 5 (9.1) |
Risk factors | |
none | 13 (23.6) |
active or ex-smokers | 31 (56.4) |
gastroesophageal reflux | 2 (3.6) |
gastroesophageal reflux and smoking | 3 (5.5) |
unknown | 6 (10.9) |
T stage | |
T X | 1 (1.8) |
T 1 | 1 (1.8) |
T 2 | 6 (10.9) |
T 3 | 36 (65.5) |
T 4 | 11 (20) |
N stage | |
N 0 | 20 (36.4) |
N 1 | 20 (36.4) |
N 2 | 12 (21.8) |
N 3 | 3 (5.5) |
Histology | |
squamous cell cancer | 53 (96.4) |
adenocarcinoma | 1 (1.8) |
verified carcinoma, unspecified | 1 (1.8) |
Grade | |
G 1 | 3 (5.5) |
G 2 | 28 (50.9) |
G 3 | 12 (21.8) |
unknown or not specified | 12 (21.8) |
Upper border of the tumor | |
≤ 18 cm from the incisors | 32 (58.2) |
18–32 cm from the incisors | 23 (41.8) |
OS | LRC | DFS | |
---|---|---|---|
Median | 20.5 months | 16.6 months | 12.9 months |
(95% CI 8.2–32.8) | (95% CI 7.3–26) | (95% CI 9.8-16.1) | |
2-year | 47% | 43.7% | 32.1% |
5-year | 19.4% | 41% | 11.5% |